Search over 3,000 reports

    Oral Mucositis - Epidemiology Forecast to 2025

    Oral Mucositis - Epidemiology Forecast to 2025
    Date: Dec, 2017
    Type: Pharmaceutical Industry Report
    Pages: 68
    Geography: Global
    Delivery Timeline: 24 hours
    SKU: DIEI0159
    DelveInsight's "Oral Mucositis - Epidemiology Forecast To 2025" report provides an overview of the disease and global historical and forecasted epidemiological data of Oral Mucositis for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan till 2025.

    Oral Mucositis is considered as one of the most common oral problems associated with cancer therapy. It is reported that Oral mucositis occurs in up to 20% to 40% of adult cancer patients receiving conventional chemotherapy for solid tumors, about 80% of patients receiving high-dose chemotherapy before haematopoietic stem cell transplantation, and almost all patients receiving radiotherapy for head and neck cancer. The Oral mucositis also occurs in the 70% of the patients with cancers of the mouth, oropharynx, hypopharynx, larynx, nasopharynx, and salivary glands. It has been reported that approximately 500,000 cases of oral mucositis occurs in U.S. The incidence of oral mucositis varies across populations of patients with cancer and is related to individual patient factors and the type of therapy being received.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house forecast model analysis by the team of industry experts.

    Scope

    • The report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options
    • The report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2015-2025
    • The report includes the overall incidence, grade specific, gender specific and indication specific incidence of Oral Mucositis in the 7MM- United States, EU5 (France, Germany, Italy, Spain and UK) and Japan?
    1. Report Introduction

    Overview
    • Oral Mucositis Incidence
    • Pathophysiology
    • Etiology and Risk Factors
    • Oral Mucositis Complications
    • Symptoms
    • Diagnosis
    • Interventions for Oral Mucositis
    • Chemotherapy Induced Oral Mucositis Treatment and Prevention
    • Treatment and Prevention Options for Patients receiving Hematopoietic Stem Cell Transplantation (HSCT)

    Epidemiology Overview
    Key Findings

    Epidemiology of Oral Mucositis in 7 MM
    • Assumptions and Rationale
    • Incident Population of Oral Mucositis in 7MM
    United States
    • Assumptions and Rationale
    • Incident Cases of Oral Mucositis in US
    • Grade Specific Incidence of Oral Mucositis in US
    • Gender Specific Incidence of Oral Mucositis in US
    • Indication Specific Incidence of Oral Mucositis in US
    EU5
    • Assumptions and Rationale
    France
    • Assumptions and Rationale
    • Incident Cases of Oral Mucositis in France
    • Grade Specific Incidence of Oral Mucositis in France
    • Gender Specific Incidence of Oral Mucositis in France
    • Indication Specific Incidence of Oral Mucositis in France
    Germany
    • Assumptions and Rationale
    • Incident Cases of Oral Mucositis in Germany
    • Grade Specific Incidence of Oral Mucositis in Germany
    • Gender Specific Incidence of Oral Mucositis in Germany
    • Indication Specific Incidence of Oral Mucositis in Germany
    Italy
    • Assumptions and Rationale
    • Incident Cases of Oral Mucositis in Italy
    • Grade Specific Incidence of Oral Mucositis in Italy
    • Gender Specific Incidence of Oral Mucositis in Italy
    • Indication Specific Incidence of Oral Mucositis in Italy
    Spain
    • Assumptions and Rationale
    • Incident Cases of Oral Mucositis in Spain
    • Grade Specific Incidence of Oral Mucositis in Spain
    • Gender Specific Incidence of Oral Mucositis in Spain
    • Indication Specific Incidence of Oral Mucositis in Spain
    United Kingdom
    • Assumptions and Rationale
    • Incident Cases of Oral Mucositis in United Kingdom
    • Grade Specific Incidence of Oral Mucositis in United Kingdom
    • Gender Specific Incidence of Oral Mucositis in United Kingdom
    • Indication Specific Incidence of Oral Mucositis in United Kingdom
    Japan
    • Assumptions and Rationale
    • Incident Cases of Oral Mucositis in Japan
    • Grade Specific Incidence of Oral Mucositis in Japan
    • Gender Specific Incidence of Oral Mucositis in Japan
    • Indication Specific Incidence of Oral Mucositis in Japan
    Appendix

    Table 1: Incident Population of Oral Mucositis in 7MM (2015-2025)
    Table 2: Incident Population of Oral Mucositis in United States (2015-2025)
    Table 3: Grade Specific Incidence of Oral Mucositis in United States (2015-2025)
    Table 4: Gender Specific Incidence of Oral Mucositis in United States (2015-2025)
    Table 5: Indication Specific Incidence of Oral Mucositis in United States (2015-2025)
    Table 6: Incident Population of Oral Mucositis in France (2015-2025)
    Table 7: Grade Specific Incidence of Oral Mucositis in France (2015-2025)
    Table 8: Gender Specific Incidence of Oral Mucositis in France (2015-2025)
    Table 9: Indication Specific Incidence of Oral Mucositis in France (2015-2025)
    Table 10: Incident Population of Oral Mucositis in Germany (2015-2025)
    Table 11: Grade Specific Incidence of Oral Mucositis in Germany (2015-2025)
    Table 12: Gender Specific Incidence of Oral Mucositis in Germany (2015-2025)
    Table 13: Indication Specific Incidence of Oral Mucositis in Germany (2015-2025)
    Table 14: Incident Population of Oral Mucositis in Italy (2015-2025)
    Table 15: Grade Specific Incidence of Oral Mucositis in Italy (2015-2025)
    Table 16: Gender Specific Incidence of Oral Mucositis in Italy (2015-2025)
    Table 17: Indication Specific Incidence of Oral Mucositis in Italy (2015-2025)
    Table 18: Incident Population of Oral Mucositis in Spain (2015-2025)
    Table 19: Grade Specific Incidence of Oral Mucositis in Spain (2015-2025)
    Table 20: Gender Specific Incidence of Oral Mucositis in Spain (2015-2025)
    Table 21: Indication Specific Incidence of Oral Mucositis in Spain (2015-2025)
    Table 22: Incident Population of Oral Mucositis in United Kingdom (2015-2025)
    Table 23: Grade Specific Incidence of Oral Mucositis in United Kingdom (2015-2025)
    Table 24: Gender Specific Incidence of Oral Mucositis in United Kingdom (2015-2025)
    Table 25: Indication Specific Incidence of Oral Mucositis in United Kingdom (2015-2025)
    Table 26: Incident Population of Oral Mucositis in Japan (2015-2025)
    Table 27: Grade Specific Incidence of Oral Mucositis in Japan (2015-2025)
    Table 28: Gender Specific Incidence of Oral Mucositis in Japan (2015-2025)
    Table 29: Indication Specific Incidence of Oral Mucositis in Japan (2015-2025)
    ?

    Figure 1: Incident Population of Oral Mucositis in 7MM (2015-2025)
    Figure 2: Incident Population of Oral Mucositis in United States (2015-2025)
    Figure 3: Grade Specific Incidence of Oral Mucositis in United States (2015-2025)
    Figure 4: Gender Specific Incidence of Oral Mucositis in United States (2015-2025)
    Figure 5: Indication Specific Incidence of Oral Mucositis in United States (2015-2025)
    Figure 6: Incident Population of Oral Mucositis in France (2015-2025)
    Figure 7: Grade Specific Incidence of Oral Mucositis in France (2015-2025)
    Figure 8: Gender Specific Incidence of Oral Mucositis in France (2015-2025)
    Figure 9: Indication Specific Incidence of Oral Mucositis in France (2015-2025)
    Figure 10: Incident Population of Oral Mucositis in Germany (2015-2025)
    Figure 11: Grade Specific Incidence of Oral Mucositis in Germany (2015-2025)
    Figure 12: Gender Specific Incidence of Oral Mucositis in Germany (2015-2025)
    Figure 13: Indication Specific Incidence of Oral Mucositis in Germany (2015-2025)
    Figure 14: Incident Population of Oral Mucositis in Italy (2015-2025)
    Figure 15: Grade Specific Incidence of Oral Mucositis in Italy (2015-2025)
    Figure 16: Gender Specific Incidence of Oral Mucositis in Italy (2015-2025)
    Figure 17: Indication Specific Incidence of Oral Mucositis in Italy (2015-2025)
    Figure 18: Incident Population of Oral Mucositis in Spain (2015-2025)
    Figure 19: Grade Specific Incidence of Oral Mucositis in Spain (2015-2025)
    Figure 20: Gender Specific Incidence of Oral Mucositis in Spain (2015-2025)
    Figure 21: Indication Specific Incidence of Oral Mucositis in Spain (2015-2025)
    Figure 22: Incident Population of Oral Mucositis in United Kingdom (2015-2025)
    Figure 23: Grade Specific Incidence of Oral Mucositis in United Kingdom (2015-2025)
    Figure 24: Gender Specific Incidence of Oral Mucositis in United Kingdom (2015-2025)
    Figure 25: Indication Specific Incidence of Oral Mucositis in United Kingdom (2015-2025)
    Figure 26: Incident Population of Oral Mucositis in Japan (2015-2025)
    Figure 27: Grade Specific Incidence of Oral Mucositis in Japan (2015-2025)
    Figure 28: Gender Specific Incidence of Oral Mucositis in Japan (2015-2025)
    Figure 29: Indication Specific Incidence of Oral Mucositis in Japan (2015-2025)
    Oral Mucositis Disease Overview

    Oral Mucositis Prevalence

    Oral Mucositis Incidence

    Oral Mucositis Risk Factors

    Oral Mucositis Epidemiology

    Oral Mucositis Patient Populations

    Oral Mucositis Diagnosed Patients

    Oral Mucositis Forecast

    Oral Mucositis Epidemiology Forecast

    Oral Mucositis Treated patients/population

    • Single User License
      (20% Off)
      $2,950.00
    • Site License
      (30% Off)
      $5,900.00
    • Global License
      (40% Off)
      $8,850.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap